Alstrom Syndrome

Genetic MONDO:0008763 Pathograph 29 Show in embeddings browser Syndromic Obesity Ciliopathy

Alstrom syndrome is a rare autosomal recessive multisystem ciliopathy caused by biallelic ALMS1 loss-of-function variants. The disease combines early retinal degeneration and progressive sensorineural hearing loss with childhood obesity, insulin resistance, type II diabetes mellitus, cardiomyopathy, and progressive kidney and liver involvement. The central mechanistic theme is ALMS1 dysfunction at centrosomes and ciliary basal bodies, with downstream defects in adipose tissue biology, sensory-cell maintenance, and fibrotic remodeling.

Ask OpenScientist

Ask a research question about Alstrom Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
1
Histopath.
17
Phenotypes
1
Gaps
29
Pathograph
1
Genes
8
Medical Actions
1
Differentials
1
Datasets
2
Trials
2
Models
1
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
Alstrom syndrome is caused by biallelic germline ALMS1 variants and shows marked age-dependent variability, including transient infantile cardiomyopathy in some patients and later adult cardiomyopathy in others.
Autosomal recessive inheritance Expressivity: VARIABLE
Show evidence (3 references)
PMID:11941369 SUPPORT Human Clinical
"Alström syndrome is a homogeneous autosomal recessive disorder that is characterized by childhood obesity associated with hyperinsulinemia, chronic hyperglycemia and neurosensory deficits."
Landmark discovery paper states the autosomal recessive inheritance pattern.
PMID:38806112 SUPPORT Human Clinical
"BACKGROUND: >40% of infants with Alström Syndrome (AS) present with a transient, severe cardiomyopathy in the first months of life, with apparent recovery in survivors. One in five individuals then develop a later-onset cardiomyopathy but wide clinical variability is observed, even within the..."
Adult cardiovascular cohort demonstrates variable expressivity across the lifespan and even within families.
PMID:20301444 SUPPORT Human Clinical
"Alström syndrome is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
GeneReviews directly supports autosomal recessive inheritance and the recurrence risks used in genetic counseling.
?

Discussions and Knowledge Gaps

1
Why do current Alms1-deficient mouse models reproduce adult cardiac dysfunction only incompletely and fail to reproduce infantile cardiomyopathy?
HUMAN MODEL MISMATCH OPEN gap_alms_cardiomyopathy_model_fidelity
Attached to
pathophysiology#Cardiac Fibroelastotic Remodeling
Human disease is biphasic, but global knockout mice had normal cardiac function at postnatal day 15 and eight weeks; only adult females developed early restrictive features. This sex- and age-limited phenotype constrains translation of mouse cardiac mechanisms and motivates complementary human iPSC and longitudinal in-vivo studies.
Show evidence (1 reference)
PMID:38756069 SUPPORT Model Organism
"Cardiac function was unaltered in Alms1 global KO mice of both sexes at postnatal day 15 (P15) and 8 weeks. At 23 weeks, female - but not male - KO mice showed increased left atrial area and decreased isovolumic relaxation time, consistent with early restrictive cardiomyopathy, as well as..."
The mouse study directly documents failure to model infantile disease and sex-limited adult cardiac abnormalities.
⚙

Pathophysiology

7
ALMS1 Basal Body Dysfunction
ALMS1 is a centrosome and ciliary basal body-associated protein. Loss of ALMS1 function disrupts basal-body dependent cellular organization across multiple tissues and acts as the upstream lesion for the sensory, renal, metabolic, and fibrotic components of Alstrom syndrome.
ALMS1 hgnc:428 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased ALMS1 (hgnc:428). hgnc:428 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
centrosome GO:0005813 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves centrosome (GO:0005813). GO:0005813 is a cellular component from the Gene Ontology. ciliary basal body GO:0036064 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves ciliary basal body (GO:0036064). GO:0036064 is a cellular component from the Gene Ontology.
Downstream
Obesity Basal body and centrosome dysfunction in ALMS1-related ciliopathy contributes directly to the childhood obesity component of Alstrom syndrome.
Relative Adipose Tissue Failure ALMS1 loss compromises adipose tissue buffering capacity and promotes metabolically adverse obesity.
Extracellular Matrix Dysregulation Cilia-linked signaling defects alter matrix remodeling programs and favor multiorgan fibrotic disease.
Kidney Ciliary Dysfunction Renal tubular primary cilia lose normal maintenance and mechanosensory function.
Photoreceptor Degeneration Photoreceptor cells progressively fail when ALMS1-dependent ciliary trafficking is lost.
Cochlear Outer Hair Cell Degeneration Hair-cell basal body dysfunction perturbs inner-ear sensory-cell polarity and survival.
Show evidence (2 references)
PMID:15855349 SUPPORT In Vitro
"We show that ALMS1 is widely expressed and localizes to centrosomes and to the base of cilia."
Cell localization experiments place ALMS1 at the centrosome and basal body, supporting a primary ciliary-basal body mechanism.
PMID:11941370 SUPPORT Human Clinical
"We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
Human genetic evidence links ALMS1 loss to disease and anchors basal body dysfunction as the upstream defect.
Relative Adipose Tissue Failure
Obesity in Alstrom syndrome is accompanied by inadequate adipose tissue expansion and adipocyte dysfunction, producing a metabolically fragile state in which insulin resistance develops early and progresses rapidly.
adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology.
Downstream
Insulin resistance Limited adipose buffering capacity accelerates systemic insulin resistance.
Type II diabetes mellitus Progressive insulin resistance drives diabetes as beta-cell compensation fails.
Hepatic steatosis Severe insulin resistance and metabolically adverse obesity contribute to common steatotic liver disease.
Acanthosis nigricans Severe insulin resistance commonly produces acanthosis nigricans as a cutaneous marker.
Hypertriglyceridemia The severe insulin-resistant metabolic state is commonly accompanied by hypertriglyceridemia.
Show evidence (1 reference)
PMID:32994277 SUPPORT Human Clinical
"Hence, we show for the first time the relative AT failure in human obese cohorts to be a major determinant of accelerated IR without evidence of lipodystrophy."
Human metabolic phenotyping identifies relative adipose tissue failure as a proximal mechanism for insulin-resistant obesity in Alstrom syndrome.
Extracellular Matrix Dysregulation
ALMS1 deficiency alters extracellular matrix regulatory programs, favoring collagen remodeling and fibroproliferative disease in liver and heart.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. collagen fibril organization GO:0030199 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves collagen fibril organization (GO:0030199). GO:0030199 is a biological process from the Gene Ontology.
Downstream
Hepatic fibrosis Dysregulated extracellular-matrix programs contribute to progressive liver fibrogenesis.
Cardiac Fibroelastotic Remodeling Abnormal matrix remodeling contributes to infantile fibroelastosis and later adult cardiomyopathy.
Show evidence (1 reference)
PMID:38062477 SUPPORT In Vitro
"alterations associated with ALMS1 depletion clustered around the processes of extracellular matrix regulation and lipid metabolism in both the transcriptome and proteome."
ALMS1 knockout fibroblast profiling directly links ALMS1 deficiency to extracellular matrix dysregulation.
Kidney Ciliary Dysfunction
Renal disease in Alstrom syndrome reflects a primary nephron ciliopathy rather than merely secondary metabolic injury, with progressive tubular ciliary loss and impaired mechanosensory signaling.
nephron tubule epithelial cell CL:1000494 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves nephron tubule epithelial cell (CL:1000494). CL:1000494 is a cell type from the Cell Ontology.
cilium organization GO:0044782 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves cilium organization (GO:0044782). GO:0044782 is a biological process from the Gene Ontology. cellular response to mechanical stimulus GO:0071260 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular response to mechanical stimulus (GO:0071260). GO:0071260 is a biological process from the Gene Ontology. ↓ DECREASED
kidney UBERON:0002113 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in kidney (UBERON:0002113). UBERON:0002113 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Chronic kidney disease Primary renal involvement progresses with age to chronic kidney disease.
Show evidence (2 references)
PMID:17206865 SUPPORT In Vitro
"Here, we show that in vitro knockdown of Alms1 in mice causes stunted cilia on kidney epithelial cells and prevents these cells from increasing calcium influx in response to mechanical stimuli."
Mouse kidney epithelial experiments show direct impairment of renal cilia morphology and mechanosensory signaling.
PMID:30064963 SUPPORT Human Clinical
"After adjusting for age, there were no significant associations of kidney dysfunction with type 2 diabetes mellitus, dyslipidemia, hypertension, cardiomyopathy or portal hypertension suggesting that kidney disease in AS is a primary manifestation of the syndrome due to lack of ALMS1 protein."
Human cohort data argue that kidney disease is a primary manifestation of ALMS rather than a secondary metabolic complication.
Photoreceptor Degeneration
ALMS1 deficiency disrupts photoreceptor intracellular trafficking and drives progressive cone and rod degeneration, producing the characteristic retinal dystrophy of Alstrom syndrome.
retinal cone cell CL:0000573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal cone cell (CL:0000573). CL:0000573 is a cell type from the Cell Ontology. retinal rod cell CL:0000604 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal rod cell (CL:0000604). CL:0000604 is a cell type from the Cell Ontology.
photoreceptor cell maintenance GO:0045494 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased photoreceptor cell maintenance (GO:0045494). GO:0045494 is a biological process from the Gene Ontology. ↓ DECREASED
retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cone/cone-rod dystrophy Progressive cone and rod loss produces the hallmark retinal dystrophy.
Visual impairment Early photoreceptor loss causes severe lifelong visual disability.
Nystagmus Infantile cone-rod dysfunction commonly presents with nystagmus.
Photophobia Early cone-rod dysfunction produces marked light sensitivity.
Show evidence (2 references)
PMID:16000322 SUPPORT Model Organism
"Diminished cone ERG b-wave response is observed early, followed by the degeneration of photoreceptor cells."
The Alms1 mouse model directly demonstrates progressive photoreceptor degeneration.
PMID:41466426 SUPPORT Human Clinical
"BACKGROUND: Alström syndrome (ALMS) is a rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in the ALMS1 gene, characterized by progressive cone-rod dystrophy, early-onset obesity, cardiomyopathy, and multiorgan dysfunction."
Large human cohort framing confirms progressive cone-rod dystrophy as a core disease manifestation.
Cochlear Outer Hair Cell Degeneration
ALMS1 localizes to cochlear hair-cell basal bodies; its loss perturbs planar cell polarity and outer hair cell survival, producing progressive sensory hearing loss.
cochlear outer hair cell CL:0000601 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear outer hair cell (CL:0000601). CL:0000601 is a cell type from the Cell Ontology.
cochlea UBERON:0001844 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cochlea (UBERON:0001844). UBERON:0001844 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Sensorineural hearing impairment Progressive predominantly sensory hearing loss reflects outer hair cell dysfunction and loss.
Show evidence (2 references)
PMID:21071598 SUPPORT Model Organism
"These results identify previously unrecognized cochlear histopathologies associated with this ciliopathy that (i) implicate ALMS1 in planar cell polarity signaling and (ii) suggest that the loss of outer hair cells causes the majority of the hearing loss in Alström Syndrome."
Mouse inner-ear studies support outer hair cell loss as the proximal lesion driving ALMS hearing loss.
PMID:28573831 SUPPORT Human Clinical
"Absent otoacoustic emissions, intact speech discrimination, and disproportionately normal auditory brainstem responses suggest an outer hair cell site of lesion."
Human audiologic phenotyping independently supports an outer hair cell lesion.
Cardiac Fibroelastotic Remodeling
Cardiac disease in Alstrom syndrome spans infantile fibroelastotic cardiomyopathy and later adult myocardial remodeling, with both cardiomyocyte and cardiac fibroblast abnormalities implicated.
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology. fibroblast of cardiac tissue CL:0002548 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast of cardiac tissue (CL:0002548). CL:0002548 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology.
heart UBERON:0000948 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart (UBERON:0000948). UBERON:0000948 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
ALMS1-knockout human iPSC-derived cardiomyocytes IPSC DERIVED MODEL The model probes cell-autonomous contractile, calcium-handling, metabolic, and senescence effects of ALMS1 loss in cardiomyocytes.
Downstream
Dilated cardiomyopathy Infantile or later myocardial remodeling can manifest as dilated cardiomyopathy in a subset of affected individuals.
Restrictive cardiomyopathy Adult-onset remodeling can produce a restrictive cardiomyopathy phenotype.
Show evidence (3 references)
PMID:34387706 SUPPORT Human Clinical
"In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
Pathology-confirmed case shows that infantile ALMS cardiomyopathy can present as primary endocardial fibroelastosis.
PMID:34387706 SUPPORT In Vitro
"ALMS1-depleted cardiomyocytes exhibited enhanced proliferation activity."
Functional studies in patient-derived systems implicate direct cardiomyocyte remodeling effects of ALMS1 deficiency.
PMID:38806112 SUPPORT Human Clinical
"Cardiomyopathy is common in adults with AS, complicated in a significant proportion by atherosclerotic coronary artery disease and restrictive cardiomyopathy, confirmed on CMR and invasive testing."
Adult cohort data show persistent structural and functional cardiac remodeling beyond infantile disease.
✶

Histopathology

1
Endocardial fibroelastosis
Rare cardiac histopathology in which infantile Alstrom cardiomyopathy is expressed as primary endocardial fibroelastosis with diffuse endocardial thickening.
Show evidence (1 reference)
PMID:34387706 SUPPORT Human Clinical
"In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
Pathology-confirmed case report links infantile Alstrom syndrome to primary endocardial fibroelastosis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Alstrom Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Cardiovascular 1
Dilated cardiomyopathy FREQUENT HP:0001644 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dilated cardiomyopathy (HP:0001644). HP:0001644 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:17594715 SUPPORT Human Clinical
"Alström syndrome is a monogenic recessive disorder featuring an array of clinical manifestations, with systemic fibrosis and multiple organ involvement, including retinal degeneration, hearing loss, childhood obesity, diabetes mellitus, dilated cardiomyopathy (DCM), urological dysfunction, and..."
Large genotype-phenotype study identifies dilated cardiomyopathy as a core multisystem feature of ALMS.
PMID:38806112 SUPPORT Human Clinical
"RESULTS: 47 adults with AS (64% male; mean age 33 years; 66% white British) were studied. Seven (15%) survived infantile cardiomyopathy and 23 (49%) developed adult-onset cardiomyopathy."
Adult cardiovascular cohort shows cardiomyopathy is frequent across the lifespan.
Digestive 2
Hepatic steatosis FREQUENT HP:0001397 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatic steatosis (HP:0001397). HP:0001397 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41466426 SUPPORT Human Clinical
"Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
Large cohort demonstrates frequent hepatic steatosis in ALMS.
Hepatic fibrosis HP:0001395 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatic fibrosis (HP:0001395). HP:0001395 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33924909 SUPPORT Human Clinical
"Patients with ALMS displayed enhanced steatosis, an early increased age-dependent LS that is associated with obesity and T2DM but also linked to genetic alterations, suggesting that ALMS1 could be involved in liver fibrogenesis."
Human liver stiffness and steatosis data support progressive fibrogenic liver involvement while qualifying the causal contribution of ALMS1.
Ear 1
Sensorineural hearing impairment FREQUENT HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28573831 SUPPORT Human Clinical
"Our data show that hearing loss associated with AS begins in childhood and is a predominantly symmetric, sensory hearing loss that may progress to a severe degree."
Prospective audiology cohort defines the typical childhood-onset progressive sensory hearing phenotype.
Endocrine 1
Type II diabetes mellitus HP:0005978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Type II diabetes mellitus (HP:0005978). HP:0005978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33566311 SUPPORT Human Clinical
"In addition, infantile transient cardiomyopathy, early childhood obesity with hyperphagia, deafness, insulin resistance (IR), type 2 diabetes mellitus (T2DM), systemic fibrosis and progressive renal or liver dysfunction are common findings."
Clinical review supports type II diabetes mellitus as a common downstream metabolic manifestation of ALMS.
Eye 3
Visual impairment OBLIGATE HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41466426 SUPPORT Human Clinical
"Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
Large cohort shows that visual impairment was universal among evaluated patients.
Nystagmus HP:0000639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nystagmus (HP:0000639). HP:0000639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
GeneReviews identifies nystagmus as an infantile manifestation of the cardinal retinal dystrophy.
Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
GeneReviews directly supports early photophobia within the retinal phenotype.
Genitourinary 1
Chronic kidney disease OCCASIONAL HP:0012622 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic kidney disease (HP:0012622). HP:0012622 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30064963 SUPPORT Human Clinical
"Eighteen percent met the definition for chronic kidney disease (eGFR < 60 mL/min/1.73 m2 and proteinuria); all were adults with median age of 32.8 (20.6-37.9) years."
Prospective NIH cohort quantifies age-progressive chronic kidney disease in adults with ALMS.
Integument 1
Acanthosis nigricans HP:0000956 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acanthosis nigricans (HP:0000956). HP:0000956 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade."
GeneReviews directly links acanthosis nigricans to the insulin-resistant phenotype.
Metabolism 2
Insulin resistance HP:0000855 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insulin resistance (HP:0000855). HP:0000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32994277 SUPPORT Human Clinical
"Here, we report on a monogenic form of IR-prone obesity, Alström syndrome (ALMS)."
Human metabolic study explicitly frames ALMS as insulin-resistance-prone obesity.
Hypertriglyceridemia VERY_FREQUENT HP:0002155 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertriglyceridemia (HP:0002155). HP:0002155 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade. Nearly all demonstrate hypertriglyceridemia."
GeneReviews' "nearly all" wording directly supports the very-frequent band.
Nervous System 1
Motor delay OCCASIONAL HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Approximately 20% of affected individuals have delay in early developmental milestones, most commonly in gross and fine motor skills."
The quantitative GeneReviews statement maps directly to the occasional frequency band.
Growth 1
Obesity VERY_FREQUENT HP:0001513 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41466426 SUPPORT Human Clinical
"Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
Large cohort shows obesity in more than 80% of evaluated patients.
Other 3
Cone/cone-rod dystrophy VERY_FREQUENT HP:0000548 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cone/cone-rod dystrophy (HP:0000548). HP:0000548 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33566311 SUPPORT Human Clinical
"The infantile cone-rod dystrophy with nystagmus and severe visual impairment is the earliest and most consistent clinical manifestation of ALMS."
Review of ALMS clinical data identifies cone-rod dystrophy as the earliest and most consistent feature.
Restrictive cardiomyopathy HP:0001723 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Restrictive cardiomyopathy (HP:0001723). HP:0001723 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Alström syndrome is characterized by cone-rod dystrophy, obesity, progressive bilateral sensorineural hearing impairment, acute infantile-onset cardiomyopathy and/or adolescent- or adult-onset restrictive cardiomyopathy, insulin resistance / type 2 diabetes mellitus (T2DM), nonalcoholic fatty..."
GeneReviews explicitly includes adolescent- or adult-onset restrictive cardiomyopathy in the core clinical spectrum.
Specific learning disability FREQUENT HP:0001328 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Learning disability, annotated with Specific learning disability (HP:0001328). HP:0001328 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"About 30% have a learning disability. Cognitive impairment (IQ <70) is very rare."
GeneReviews quantifies learning disability at 30%, supporting the frequent band and distinguishing it from rare global cognitive impairment.
🧬

Genetic Associations

1
ALMS1 (Causative)
Gene: ALMS1 hgnc:428 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ALMS1 (hgnc:428). hgnc:428 is a gene from the HUGO Gene Nomenclature Committee.
Autosomal recessive
Show evidence (3 references)
PMID:11941370 SUPPORT Human Clinical
"We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
Original positional cloning study establishes ALMS1 as the causative gene and shows recurrent truncating alleles.
PMID:41466426 SUPPORT Human Clinical
"A total of 132 distinct ALMS1 variants (254 alleles) were identified, including 64 novel variants. Truncating mutations predominated (nonsense: 46.9%, frameshift: 45.3%)."
Large contemporary cohort confirms that truncating ALMS1 variants predominate and substantially expands the pathogenic variant spectrum.
PMID:41466426 SUPPORT Human Clinical
"Echocardiographic analysis of 34 patients revealed exon 16 truncating variants were significantly associated with infantile-onset cardiomyopathy (72.7% vs. 30.4%, p < 0.05)."
This cohort provides direct support for the stated exon 16 genotype-phenotype enrichment.
💊

Medical Actions

8
GLP-1 Receptor Agonist Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: semaglutide CHEBI:167574 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses semaglutide (CHEBI:167574). CHEBI:167574 is a therapeutic agent from Chemical Entities of Biological Interest. exendin-4 CHEBI:64073 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses exendin-4 (CHEBI:64073). CHEBI:64073 is a therapeutic agent from Chemical Entities of Biological Interest.
Semaglutide or exenatide can improve weight, glycemia, and lipid parameters in adults with Alstrom syndrome and metabolically significant obesity or diabetes.
Target Phenotypes: Obesity HP:0001513 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology. Type II diabetes mellitus HP:0005978 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Type II diabetes mellitus (HP:0005978). HP:0005978 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38151964 SUPPORT Human Clinical
"completed 6 months of treatment with GLP-1 RAs either in the form of semaglutide or exenatide"
The abstract identifies both agents used in the Alstrom syndrome cohort.
PMID:38151964 SUPPORT Human Clinical
"equating to 6% weight loss (P < .01) and 1.1% absolute reduction in HbA1c (P < .01)"
The abstract quantifies clinically relevant weight and glycemic improvements after six months.
Reduced-Calorie Dietary Management
Category: Therapeutic Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
A healthful reduced-calorie diet with restricted simple carbohydrate intake is a foundational management strategy for obesity and insulin resistance.
Target Phenotypes: Obesity HP:0001513 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology. Insulin resistance HP:0000855 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Insulin resistance (HP:0000855). HP:0000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Obesity and insulin resistance are managed by a healthful, reduced-calorie diet with restricted simple carbohydrate intake and regular aerobic exercise."
GeneReviews directly supports diet and exercise as foundational metabolic management.
Hearing aid usage
Sound amplification is beneficial for the common progressive sensory hearing loss of Alstrom syndrome.
Target Phenotypes: Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28573831 SUPPORT Human Clinical
"These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
Prospective audiology cohort supports hearing aids as routine symptomatic treatment for ALMS hearing loss.
Cochlear implantation
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Cochlear implantation should be considered for severe or functionally limiting hearing loss not adequately managed with amplification.
Target Phenotypes: Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28573831 SUPPORT Human Clinical
"These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
Same cohort specifically identifies cochlear implantation as an option for more severe ALMS hearing loss.
Genetic Counseling and Reproductive Planning
Category: Counseling / Informational Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counseling explains autosomal recessive recurrence risks and the availability of carrier, prenatal, and preimplantation genetic testing once familial ALMS1 variants are known.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
GeneReviews provides the autosomal recessive recurrence risks communicated in genetic counseling.
Multisystem Surveillance
Category: Monitoring
Longitudinal monitoring should cover vision, hearing, growth and weight, cardiac imaging and electrophysiology, glucose control, lipids, liver and thyroid function, and regular renal laboratory and ultrasound assessment.
Show evidence (2 references)
PMID:20301444 SUPPORT Human Clinical
"Surveillance: Routine assessment of vision and hearing; weight, height, and body mass index; heart (including echocardiography and EKG in all individuals, and MRI in those age >18 years); postprandial c-peptide and glucose and HbA1C starting at age four years; lipid profile; plasma ALT, AST, and..."
GeneReviews gives an age-aware multisystem surveillance schedule.
PMID:20301444 SUPPORT Human Clinical
"Twice-yearly CBC, electrolytes, BUN, creatinine, cystatin-C, uric acid, urinalysis. Renal and bladder ultrasound examinations every one to two years if symptomatic and/or if urinalysis is abnormal."
GeneReviews specifies the renal laboratory and imaging cadence.
Standard Heart Failure and Cardiomyopathy Management
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Dilated or restrictive cardiomyopathy and heart failure require standard guideline-directed cardiac management individualized to phenotype and age.
Target Phenotypes: Dilated cardiomyopathy HP:0001644 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Dilated cardiomyopathy (HP:0001644). HP:0001644 is a phenotype from the Human Phenotype Ontology. Restrictive cardiomyopathy HP:0001723 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Restrictive cardiomyopathy (HP:0001723). HP:0001723 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Standard therapy for heart failure / cardiomyopathy."
GeneReviews explicitly recommends standard treatment for the cardiac manifestations.
Avoidance of Glitazones in Cardiac Failure
Category: Therapeutic
Diabetes management must account for multisystem disease; glitazone therapy is contraindicated when cardiac failure is present.
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"Therapy directed at one system may have adverse effects on other systems; for example, the use of glitazone therapy in diabetes mellitus is contraindicated in the presence of cardiac failure."
GeneReviews directly states this disease-specific cross-system medication warning.
🔬

Diagnosis

2
Age-dependent clinical assessment
Clinical suspicion rests on cardinal manifestations that emerge across infancy, childhood, and early adulthood; early cone-rod dystrophy, nystagmus, photophobia, infantile obesity, and cardiomyopathy are important red flags, but absence of a later feature does not exclude the diagnosis.
Show evidence (2 references)
PMID:20301444 SUPPORT Human Clinical
"The clinical diagnosis of Alström syndrome is based on cardinal clinical features that emerge throughout infancy, childhood, and young adulthood."
GeneReviews establishes the age-dependent clinical-diagnosis framework.
PMID:39763001 SUPPORT Human Clinical
"Obesity rapidly developing in infancy should be flagged as a key symptom to be aware of where AS is a possible diagnosis."
A contemporary diagnostic-pathway cohort identifies rapidly developing infantile obesity as a red flag.
Molecular genetic testing of ALMS1
Molecular diagnosis is established by identifying biallelic pathogenic ALMS1 variants; testing is particularly important because the multisystem phenotype is progressive and age dependent.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:20301444 SUPPORT Human Clinical
"The molecular diagnosis of Alström syndrome is established in individuals of all ages by identification of biallelic pathogenic variants in ALMS1 on molecular genetic testing."
GeneReviews directly defines the confirmatory molecular test.
📊

Prevalence

1
Global
Point Prevalence 0.1 per 100,000 1–9 per 1,000,000
Show evidence (1 reference)
PMID:33566311 SUPPORT Human Clinical
"BACKGROUND: Alström syndrome (ALMS) is a monogenic ultra-rare disorder with a prevalence of one per million inhabitants caused by pathogenic variants of ALMS1 gene."
Review of ALMS clinical and molecular literature provides a conventional global prevalence estimate of about one per million.
🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Alstrom Syndrome:

Bardet-Biedl syndrome MONDO:0015229
Overlapping Features Both conditions are autosomal recessive syndromic-obesity ciliopathies with retinal and renal involvement, making early clinical confusion possible.
Distinguishing Features
  • Early cone-rod dystrophy, progressive sensorineural hearing loss, and cardiomyopathy favor Alstrom syndrome.
  • Postaxial polydactyly and the canonical BBS gene spectrum favor Bardet-Biedl syndrome.
  • Biallelic pathogenic variants in ALMS1 establish Alstrom syndrome.
Show evidence (1 reference)
PMID:39763001 SUPPORT Human Clinical
"A total of 2/17 (12%) patients in our study received an incorrect diagnosis of Bardet-Biedl Syndrome and Leber Congenital Amaurosis"
The diagnostic-pathway cohort documents real-world confusion with Bardet-Biedl syndrome and the resolving role of genetic testing.
📊

Related Datasets

1
Metabolomic data of ALMS1 WT and ALMS1 KO mice before and after symptoms of Alstrom syndrome massive:MSV000099396
RAW metabolomics data from Mus musculus liver, plasma and WAT used in - Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis. The dataset includes files from ALMS1 KO and WT mice (young and adult)
mouse METABOLOMICS
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Alstrom Syndrome"). Retrieved 2026-08-02.
🔬

Clinical Trials

2
NCT03746522 PHASE_III COMPLETED
Randomized placebo-controlled Phase III study of the MC4R agonist setmelanotide for obesity and hyperphagia in Bardet-Biedl and Alstrom syndromes. Only six participants had Alstrom syndrome, and the published ALMS-specific efficacy result was inconclusive.
Target Phenotypes: Obesity HP:0001513 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
clinicaltrials:NCT03746522 SUPPORT Human Clinical
"This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS)."
ClinicalTrials.gov establishes the intervention, population, phase, and intended obesity/hyperphagia outcomes.
PMID:36356613 SUPPORT Human Clinical
"Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome."
The trial publication prevents extrapolation of the positive Bardet-Biedl result to the underpowered Alstrom subgroup.
NCT03184584 PHASE_II TERMINATED
Open-label rollover study of the investigational antifibrotic PBI-4050 in participants who completed an earlier sponsor study. The registry describes a combined Phase II/III design; represented as Phase II because the schema accepts one phase value and the cached summary calls it Phase II.
Show evidence (1 reference)
clinicaltrials:NCT03184584 SUPPORT Human Clinical
"Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050."
ClinicalTrials.gov establishes this disease-specific investigational study without implying efficacy.
🧫

Experimental Models

1
ALMS1-knockout human iPSC-derived cardiomyocytes IPSC_DERIVED_MODEL
ALMS1 knockout isogenic wild-type control
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Tissue
heart UBERON:0000948 Uberon multi-species anatomy ontology (UBERON) Relation: this experimental model uses this anatomical location This experimental model uses heart (UBERON:0000948). UBERON:0000948 is an anatomical location from the Uberon multi-species anatomy ontology.
Cell source
Human induced pluripotent stem cells differentiated into cardiomyocytes
Culture
Monolayer iPSC-derived cardiomyocyte culture
Publication
PMID:39243575
Pathograph links
Cardiac Fibroelastotic Remodeling The model probes cell-autonomous contractile, calcium-handling, metabolic, and senescence effects of ALMS1 loss in cardiomyocytes.
Show evidence (1 reference)
PMID:39243575 SUPPORT In Vitro
"To understand the role of ALMS1 in infantile cardiomyopathy, the reduction of ALMS1 protein seen in AS patients was modelled using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), in which ALMS1 was knocked out."
The study explicitly establishes this human iPSC cardiomyocyte system as an infantile-cardiomyopathy model.
Findings
ALMS1 knockout alters cardiomyocyte contractility, calcium handling, energetics, and senescence.
"MuscleMotion analysis and calcium optical mapping experiments suggest that ALMS1 knockout (KO) cells have increased contractility, with altered calcium extrusion and impaired calcium handling dynamics compared to wildtype (WT) counterparts."
Show evidence (1 reference)
PMID:39243575 SUPPORT In Vitro
"MuscleMotion analysis and calcium optical mapping experiments suggest that ALMS1 knockout (KO) cells have increased contractility, with altered calcium extrusion and impaired calcium handling dynamics compared to wildtype (WT) counterparts."
Directly reports abnormal contractility and calcium handling in the model.
Show evidence (1 reference)
PMID:39243575 SUPPORT In Vitro
"Overall, this study provides insights into the molecular mechanisms in AS, particularly the role of ALMS1 in infantile cardiomyopathy in AS, using iPSC-CMs as a 'disease in a dish' model to provide insights into multiple aspects of this complex disease."
Supports the model's disease relevance while keeping its in-vitro evidence class explicit.
🐁

Animal Models

1
Homozygous Alms1 gene-trap disruption (Alms1-/-) Mouse (Mus musculus) Knockout mouse
Alms1-disrupted mice reproduce retinal degeneration, late-onset hearing loss, obesity, hyperinsulinemia, and insulin resistance, making them useful for the sensory and metabolic arms of the disease while not fully modeling the human cardiac spectrum.
Obesity Insulin resistance Photoreceptor degeneration Late-onset hearing loss
Species
Mouse (Mus musculus)
Genotype
Homozygous Alms1 gene-trap disruption (Alms1-/-)
Genes
ALMS1 hgnc:428 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns ALMS1 (hgnc:428). hgnc:428 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:16000322 SUPPORT Model Organism
"Alms1-/- mice develop features similar to patients with AS, including obesity, hypogonadism, hyperinsulinemia, retinal dysfunction and late-onset hearing loss."
The foundational mouse-model paper documents multisystem phenotypic recapitulation.
{ }

Source YAML

click to show 
name: Alstrom Syndrome
creation_date: '2026-04-12T20:00:00Z'
description: >-
  Alstrom syndrome is a rare autosomal recessive multisystem ciliopathy caused by
  biallelic ALMS1 loss-of-function variants. The disease combines early retinal
  degeneration and progressive sensorineural hearing loss with childhood obesity,
  insulin resistance, type II diabetes mellitus, cardiomyopathy, and progressive
  kidney and liver involvement. The central mechanistic theme is ALMS1
  dysfunction at centrosomes and ciliary basal bodies, with downstream defects
  in adipose tissue biology, sensory-cell maintenance, and fibrotic remodeling.
category: Genetic
parents:
- Syndromic Obesity
- Ciliopathy
disease_term:
  preferred_term: Alstrom syndrome
  description: Rare autosomal recessive ALMS1-related multisystem ciliopathy.
  term:
    id: MONDO:0008763
    label: Alstrom syndrome
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.1
  percentage: 1 in 1,000,000
  evidence:
  - reference: PMID:33566311
    reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BACKGROUND: Alström syndrome (ALMS) is a monogenic ultra-rare disorder with a prevalence of one per million inhabitants caused by pathogenic variants of ALMS1 gene."
    explanation: Review of ALMS clinical and molecular literature provides a conventional global prevalence estimate of about one per million.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  expressivity: VARIABLE
  description: >-
    Alstrom syndrome is caused by biallelic germline ALMS1 variants and shows
    marked age-dependent variability, including transient infantile
    cardiomyopathy in some patients and later adult cardiomyopathy in others.
  evidence:
  - reference: PMID:11941369
    reference_title: "Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alström syndrome is a homogeneous autosomal recessive disorder that is characterized by childhood obesity associated with hyperinsulinemia, chronic hyperglycemia and neurosensory deficits."
    explanation: Landmark discovery paper states the autosomal recessive inheritance pattern.
  - reference: PMID:38806112
    reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BACKGROUND: >40% of infants with Alström Syndrome (AS) present with a transient, severe cardiomyopathy in the first months of life, with apparent recovery in survivors. One in five individuals then develop a later-onset cardiomyopathy but wide clinical variability is observed, even within the same family."
    explanation: Adult cardiovascular cohort demonstrates variable expressivity across the lifespan and even within families.
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alström syndrome is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: GeneReviews directly supports autosomal recessive inheritance and the recurrence risks used in genetic counseling.
genetic:
- name: ALMS1
  gene_term:
    preferred_term: ALMS1
    term:
      id: hgnc:428
      label: ALMS1
  association: Causative
  features: >-
    Biallelic truncating variants predominate. Large cohort studies continue to
    expand the mutational spectrum and suggest genotype-phenotype enrichment
    of infantile cardiomyopathy with exon 16 truncating variants.
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alström syndrome is inherited in an autosomal recessive manner."
      explanation: GeneReviews directly supports the inheritance assignment attached to ALMS1.
  evidence:
  - reference: PMID:11941370
    reference_title: "Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
    explanation: Original positional cloning study establishes ALMS1 as the causative gene and shows recurrent truncating alleles.
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 132 distinct ALMS1 variants (254 alleles) were identified, including 64 novel variants. Truncating mutations predominated (nonsense: 46.9%, frameshift: 45.3%)."
    explanation: Large contemporary cohort confirms that truncating ALMS1 variants predominate and substantially expands the pathogenic variant spectrum.
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Echocardiographic analysis of 34 patients revealed exon 16 truncating variants were significantly associated with infantile-onset cardiomyopathy (72.7% vs. 30.4%, p < 0.05)."
    explanation: This cohort provides direct support for the stated exon 16 genotype-phenotype enrichment.
pathophysiology:
- name: ALMS1 Basal Body Dysfunction
  biological_scale: CELLULAR
  conforms_to: "ciliopathy_dysfunction#Basal Body and Transition Zone Dysfunction"
  description: >-
    ALMS1 is a centrosome and ciliary basal body-associated protein. Loss of
    ALMS1 function disrupts basal-body dependent cellular organization across
    multiple tissues and acts as the upstream lesion for the sensory, renal,
    metabolic, and fibrotic components of Alstrom syndrome.
  gene:
    preferred_term: ALMS1
    modifier: DECREASED
    term:
      id: hgnc:428
      label: ALMS1
  cellular_components:
  - preferred_term: centrosome
    term:
      id: GO:0005813
      label: centrosome
  - preferred_term: ciliary basal body
    term:
      id: GO:0036064
      label: ciliary basal body
  evidence:
  - reference: PMID:15855349
    reference_title: "Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show that ALMS1 is widely expressed and localizes to centrosomes and to the base of cilia."
    explanation: Cell localization experiments place ALMS1 at the centrosome and basal body, supporting a primary ciliary-basal body mechanism.
  - reference: PMID:11941370
    reference_title: "Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
    explanation: Human genetic evidence links ALMS1 loss to disease and anchors basal body dysfunction as the upstream defect.
  downstream:
  - target: Obesity
    description: >-
      Basal body and centrosome dysfunction in ALMS1-related ciliopathy
      contributes directly to the childhood obesity component of Alstrom
      syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15855349
      reference_title: >-
        Subcellular localization of ALMS1 supports involvement of centrosome
        and basal body dysfunction in the pathogenesis of obesity, insulin
        resistance, and type 2 diabetes.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Coupled with recent data on the complex phenotype of Bardet-Biedl syndrome, our findings imply an unexpected central role for basal body and centrosome dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes."
      explanation: >-
        The localization study connects ALMS1 basal-body biology with obesity
        pathogenesis but does not resolve the intervening tissue and signaling
        mechanisms, so it only partially supports this indirect edge.
  - target: Relative Adipose Tissue Failure
    description: ALMS1 loss compromises adipose tissue buffering capacity and promotes metabolically adverse obesity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32994277
      reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "relative AT failure in human obese cohorts to be a major determinant of accelerated IR"
      explanation: Human metabolic phenotyping supports adipose failure in ALMS, while the intervening route from basal-body dysfunction remains unresolved.
  - target: Extracellular Matrix Dysregulation
    description: Cilia-linked signaling defects alter matrix remodeling programs and favor multiorgan fibrotic disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38062477
      reference_title: "Loss of the centrosomal protein ALMS1 alters lipid metabolism and the regulation of extracellular matrix-related processes."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "alterations associated with ALMS1 depletion clustered around the processes of extracellular matrix regulation and lipid metabolism in both the transcriptome and proteome."
      explanation: ALMS1-depleted fibroblasts directly connect loss of the centrosomal protein to extracellular-matrix regulatory changes, although intermediate signaling is not resolved.
  - target: Kidney Ciliary Dysfunction
    description: Renal tubular primary cilia lose normal maintenance and mechanosensory function.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17206865
      reference_title: "A role for Alström syndrome protein, alms1, in kidney ciliogenesis and cellular quiescence."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "in vitro knockdown of Alms1 in mice causes stunted cilia on kidney epithelial cells and prevents these cells from increasing calcium influx in response to mechanical stimuli."
      explanation: Experimental Alms1 depletion directly impairs renal epithelial cilia and mechanosensory signaling.
  - target: Photoreceptor Degeneration
    description: Photoreceptor cells progressively fail when ALMS1-dependent ciliary trafficking is lost.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:16000322
      reference_title: "Alms1-disrupted mice recapitulate human Alström syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Diminished cone ERG b-wave response is observed early, followed by the degeneration of photoreceptor cells."
      explanation: Alms1 disruption produces early functional cone deficits followed by photoreceptor loss in vivo.
  - target: Cochlear Outer Hair Cell Degeneration
    description: Hair-cell basal body dysfunction perturbs inner-ear sensory-cell polarity and survival.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21071598
      reference_title: "Alström Syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the loss of outer hair cells causes the majority of the hearing loss in Alström Syndrome."
      explanation: The inner-ear model links ALMS1-dependent planar-cell-polarity disruption to outer-hair-cell loss.
- name: Relative Adipose Tissue Failure
  biological_scale: TISSUE
  description: >-
    Obesity in Alstrom syndrome is accompanied by inadequate adipose tissue
    expansion and adipocyte dysfunction, producing a metabolically fragile state
    in which insulin resistance develops early and progresses rapidly.
  cell_types:
  - preferred_term: adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  evidence:
  - reference: PMID:32994277
    reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hence, we show for the first time the relative AT failure in human obese cohorts to be a major determinant of accelerated IR without evidence of lipodystrophy."
    explanation: Human metabolic phenotyping identifies relative adipose tissue failure as a proximal mechanism for insulin-resistant obesity in Alstrom syndrome.
  downstream:
  - target: Insulin resistance
    description: Limited adipose buffering capacity accelerates systemic insulin resistance.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32994277
      reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "relative AT failure in human obese cohorts to be a major determinant of accelerated IR"
      explanation: Human metabolic phenotyping directly identifies relative adipose-tissue failure as a determinant of accelerated insulin resistance.
  - target: Type II diabetes mellitus
    description: Progressive insulin resistance drives diabetes as beta-cell compensation fails.
    evidence:
    - reference: PMID:33566311
      reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both extreme IR and β-cell failure are the two determinant factors responsible for the development of glucose metabolism alterations in ALMS."
      explanation: Clinical review directly supports progression from severe insulin resistance and beta-cell failure to dysglycemia and type II diabetes in ALMS.
  - target: Hepatic steatosis
    description: Severe insulin resistance and metabolically adverse obesity contribute to common steatotic liver disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33924909
      reference_title: "Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with ALMS displayed enhanced steatosis, an early increased age-dependent LS that is associated with obesity and T2DM but also linked to genetic alterations, suggesting that ALMS1 could be involved in liver fibrogenesis."
      explanation: Human liver phenotyping links steatosis and liver stiffness to obesity and T2DM while preserving an additional ALMS1-specific contribution.
  - target: Acanthosis nigricans
    description: Severe insulin resistance commonly produces acanthosis nigricans as a cutaneous marker.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans"
      explanation: GeneReviews directly connects insulin resistance, the established intermediate, with acanthosis nigricans.
  - target: Hypertriglyceridemia
    description: The severe insulin-resistant metabolic state is commonly accompanied by hypertriglyceridemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade. Nearly all demonstrate hypertriglyceridemia."
      explanation: GeneReviews places near-universal hypertriglyceridemia in the same insulin-resistance progression, supporting this clinically mediated edge.
- name: Extracellular Matrix Dysregulation
  biological_scale: TISSUE
  description: >-
    ALMS1 deficiency alters extracellular matrix regulatory programs, favoring
    collagen remodeling and fibroproliferative disease in liver and heart.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: collagen fibril organization
    term:
      id: GO:0030199
      label: collagen fibril organization
  evidence:
  - reference: PMID:38062477
    reference_title: "Loss of the centrosomal protein ALMS1 alters lipid metabolism and the regulation of extracellular matrix-related processes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "alterations associated with ALMS1 depletion clustered around the processes of extracellular matrix regulation and lipid metabolism in both the transcriptome and proteome."
    explanation: ALMS1 knockout fibroblast profiling directly links ALMS1 deficiency to extracellular matrix dysregulation.
  downstream:
  - target: Hepatic fibrosis
    description: Dysregulated extracellular-matrix programs contribute to progressive liver fibrogenesis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33924909
      reference_title: "Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with ALMS displayed enhanced steatosis, an early increased age-dependent LS that is associated with obesity and T2DM but also linked to genetic alterations, suggesting that ALMS1 could be involved in liver fibrogenesis."
      explanation: Human elastography and ultrasound data support age-dependent fibrogenic liver involvement while appropriately qualifying the ALMS1-specific mechanism as suggested rather than proven.
  - target: Cardiac Fibroelastotic Remodeling
    description: Abnormal matrix remodeling contributes to infantile fibroelastosis and later adult cardiomyopathy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34387706
      reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
      explanation: Pathology confirms fibroelastotic cardiac remodeling in ALMS, but a direct causal route from the broader extracellular-matrix program is not established.
- name: Kidney Ciliary Dysfunction
  biological_scale: TISSUE
  conforms_to: "ciliopathy_dysfunction#Renal Tubular Cystic and Fibrotic Disease"
  description: >-
    Renal disease in Alstrom syndrome reflects a primary nephron ciliopathy
    rather than merely secondary metabolic injury, with progressive tubular
    ciliary loss and impaired mechanosensory signaling.
  cell_types:
  - preferred_term: nephron tubule epithelial cell
    term:
      id: CL:1000494
      label: nephron tubule epithelial cell
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  biological_processes:
  - preferred_term: cilium organization
    term:
      id: GO:0044782
      label: cilium organization
  - preferred_term: cellular response to mechanical stimulus
    modifier: DECREASED
    term:
      id: GO:0071260
      label: cellular response to mechanical stimulus
  evidence:
  - reference: PMID:17206865
    reference_title: "A role for Alström syndrome protein, alms1, in kidney ciliogenesis and cellular quiescence."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, we show that in vitro knockdown of Alms1 in mice causes stunted cilia on kidney epithelial cells and prevents these cells from increasing calcium influx in response to mechanical stimuli."
    explanation: Mouse kidney epithelial experiments show direct impairment of renal cilia morphology and mechanosensory signaling.
  - reference: PMID:30064963
    reference_title: "Alström syndrome: Renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After adjusting for age, there were no significant associations of kidney dysfunction with type 2 diabetes mellitus, dyslipidemia, hypertension, cardiomyopathy or portal hypertension suggesting that kidney disease in AS is a primary manifestation of the syndrome due to lack of ALMS1 protein."
    explanation: Human cohort data argue that kidney disease is a primary manifestation of ALMS rather than a secondary metabolic complication.
  downstream:
  - target: Chronic kidney disease
    description: Primary renal involvement progresses with age to chronic kidney disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alström syndrome is characterized by cone-rod dystrophy, obesity, progressive bilateral sensorineural hearing impairment, acute infantile-onset cardiomyopathy and/or adolescent- or adult-onset restrictive cardiomyopathy, insulin resistance / type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and chronic progressive kidney disease."
      explanation: GeneReviews identifies chronic progressive kidney disease as part of the core clinical spectrum.
- name: Photoreceptor Degeneration
  biological_scale: CELLULAR
  conforms_to: "ciliopathy_dysfunction#Photoreceptor Connecting Cilium Degeneration"
  description: >-
    ALMS1 deficiency disrupts photoreceptor intracellular trafficking and drives
    progressive cone and rod degeneration, producing the characteristic retinal
    dystrophy of Alstrom syndrome.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    modifier: DECREASED
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
  evidence:
  - reference: PMID:16000322
    reference_title: "Alms1-disrupted mice recapitulate human Alström syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Diminished cone ERG b-wave response is observed early, followed by the degeneration of photoreceptor cells."
    explanation: The Alms1 mouse model directly demonstrates progressive photoreceptor degeneration.
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BACKGROUND: Alström syndrome (ALMS) is a rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in the ALMS1 gene, characterized by progressive cone-rod dystrophy, early-onset obesity, cardiomyopathy, and multiorgan dysfunction."
    explanation: Large human cohort framing confirms progressive cone-rod dystrophy as a core disease manifestation.
  downstream:
  - target: Cone/cone-rod dystrophy
    description: Progressive cone and rod loss produces the hallmark retinal dystrophy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16000322
      reference_title: "Alms1-disrupted mice recapitulate human Alström syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Diminished cone ERG b-wave response is observed early, followed by the degeneration of photoreceptor cells."
      explanation: The Alms1 model directly links progressive photoreceptor loss with cone functional decline.
  - target: Visual impairment
    description: Early photoreceptor loss causes severe lifelong visual disability.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33566311
      reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The infantile cone-rod dystrophy with nystagmus and severe visual impairment is the earliest and most consistent clinical manifestation of ALMS."
      explanation: Clinical evidence connects infantile cone-rod dystrophy with severe visual impairment.
  - target: Nystagmus
    description: Infantile cone-rod dysfunction commonly presents with nystagmus.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
      explanation: GeneReviews places nystagmus within the early clinical presentation of cone-rod dystrophy.
  - target: Photophobia
    description: Early cone-rod dysfunction produces marked light sensitivity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301444
      reference_title: "Alström Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
      explanation: GeneReviews places photophobia within the early clinical presentation of cone-rod dystrophy.
- name: Cochlear Outer Hair Cell Degeneration
  biological_scale: CELLULAR
  description: >-
    ALMS1 localizes to cochlear hair-cell basal bodies; its loss perturbs planar
    cell polarity and outer hair cell survival, producing progressive sensory
    hearing loss.
  cell_types:
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  locations:
  - preferred_term: cochlea
    term:
      id: UBERON:0001844
      label: cochlea
  evidence:
  - reference: PMID:21071598
    reference_title: "Alström Syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These results identify previously unrecognized cochlear histopathologies associated with this ciliopathy that (i) implicate ALMS1 in planar cell polarity signaling and (ii) suggest that the loss of outer hair cells causes the majority of the hearing loss in Alström Syndrome."
    explanation: Mouse inner-ear studies support outer hair cell loss as the proximal lesion driving ALMS hearing loss.
  - reference: PMID:28573831
    reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Absent otoacoustic emissions, intact speech discrimination, and disproportionately normal auditory brainstem responses suggest an outer hair cell site of lesion."
    explanation: Human audiologic phenotyping independently supports an outer hair cell lesion.
  downstream:
  - target: Sensorineural hearing impairment
    description: Progressive predominantly sensory hearing loss reflects outer hair cell dysfunction and loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21071598
      reference_title: "Alström Syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the loss of outer hair cells causes the majority of the hearing loss in Alström Syndrome."
      explanation: Cochlear experiments identify outer-hair-cell loss as the principal driver of ALMS hearing loss.
- name: Cardiac Fibroelastotic Remodeling
  biological_scale: TISSUE
  description: >-
    Cardiac disease in Alstrom syndrome spans infantile fibroelastotic
    cardiomyopathy and later adult myocardial remodeling, with both
    cardiomyocyte and cardiac fibroblast abnormalities implicated.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: fibroblast of cardiac tissue
    term:
      id: CL:0002548
      label: fibroblast of cardiac tissue
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:34387706
    reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
    explanation: Pathology-confirmed case shows that infantile ALMS cardiomyopathy can present as primary endocardial fibroelastosis.
  - reference: PMID:34387706
    reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ALMS1-depleted cardiomyocytes exhibited enhanced proliferation activity."
    explanation: Functional studies in patient-derived systems implicate direct cardiomyocyte remodeling effects of ALMS1 deficiency.
  - reference: PMID:38806112
    reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cardiomyopathy is common in adults with AS, complicated in a significant proportion by atherosclerotic coronary artery disease and restrictive cardiomyopathy, confirmed on CMR and invasive testing."
    explanation: Adult cohort data show persistent structural and functional cardiac remodeling beyond infantile disease.
  downstream:
  - target: Dilated cardiomyopathy
    description: Infantile or later myocardial remodeling can manifest as dilated cardiomyopathy in a subset of affected individuals.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11941369
      reference_title: "Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The gene involved in Alström syndrome probably interacts with genetic modifiers, as subsets of affected individuals present with additional features such as dilated cardiomyopathy, hepatic dysfunction, hypothyroidism, male hypogonadism, short stature and mild to moderate developmental delay, and with secondary complications normally associated with type 2 diabetes, such as hyperlipidemia and atherosclerosis."
      explanation: Human genetic observations establish dilated cardiomyopathy in the ALMS spectrum, while only partially supporting the proposed intervening remodeling mechanism.
  - target: Restrictive cardiomyopathy
    description: Adult-onset remodeling can produce a restrictive cardiomyopathy phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38806112
      reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cardiomyopathy is common in adults with AS, complicated in a significant proportion by atherosclerotic coronary artery disease and restrictive cardiomyopathy, confirmed on CMR and invasive testing."
      explanation: Adult cardiovascular phenotyping directly supports restrictive cardiomyopathy within the ALMS cardiac spectrum.
histopathology:
- name: Endocardial fibroelastosis
  finding_term:
    preferred_term: Cardiac Fibrosis
    term:
      id: NCIT:C178564
      label: Cardiac Fibrosis
  context: Infantile severe cardiomyopathy
  description: >-
    Rare cardiac histopathology in which infantile Alstrom cardiomyopathy is
    expressed as primary endocardial fibroelastosis with diffuse endocardial
    thickening.
  evidence:
  - reference: PMID:34387706
    reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
    explanation: Pathology-confirmed case report links infantile Alstrom syndrome to primary endocardial fibroelastosis.
phenotypes:
- category: Ophthalmologic
  name: Cone/cone-rod dystrophy
  description: >-
    Early progressive retinal degeneration involving cones and rods, often
    beginning in infancy and driving lifelong visual disability.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Cone/cone-rod dystrophy
    term:
      id: HP:0000548
      label: Cone/cone-rod dystrophy
  evidence:
  - reference: PMID:33566311
    reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The infantile cone-rod dystrophy with nystagmus and severe visual impairment is the earliest and most consistent clinical manifestation of ALMS."
    explanation: Review of ALMS clinical data identifies cone-rod dystrophy as the earliest and most consistent feature.
- category: Ophthalmologic
  name: Visual impairment
  description: Severe early-onset visual loss caused by progressive retinal degeneration.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
    explanation: Large cohort shows that visual impairment was universal among evaluated patients.
- category: Ophthalmologic
  name: Nystagmus
  description: Infantile nystagmus accompanies the earliest cone-rod dystrophy and is an important diagnostic clue.
  diagnostic: true
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
    explanation: GeneReviews identifies nystagmus as an infantile manifestation of the cardinal retinal dystrophy.
- category: Ophthalmologic
  name: Photophobia
  description: Early photophobia accompanies progressive cone-rod dysfunction.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cone-rod dystrophy presents as progressive visual impairment, photophobia, and nystagmus usually starting between birth and age 15 months."
    explanation: GeneReviews directly supports early photophobia within the retinal phenotype.
- category: Otologic
  name: Sensorineural hearing impairment
  description: Progressive, usually symmetric sensory hearing loss beginning in childhood.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:28573831
    reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data show that hearing loss associated with AS begins in childhood and is a predominantly symmetric, sensory hearing loss that may progress to a severe degree."
    explanation: Prospective audiology cohort defines the typical childhood-onset progressive sensory hearing phenotype.
- category: Endocrine/Metabolic
  name: Obesity
  description: Early-onset obesity, often beginning in childhood and frequently truncal in distribution.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
    explanation: Large cohort shows obesity in more than 80% of evaluated patients.
- category: Endocrine/Metabolic
  name: Insulin resistance
  description: Early and often severe insulin resistance complicating obesity in Alstrom syndrome.
  phenotype_term:
    preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: PMID:32994277
    reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report on a monogenic form of IR-prone obesity, Alström syndrome (ALMS)."
    explanation: Human metabolic study explicitly frames ALMS as insulin-resistance-prone obesity.
- category: Dermatologic
  name: Acanthosis nigricans
  description: Cutaneous acanthosis nigricans commonly accompanies severe insulin resistance.
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade."
    explanation: GeneReviews directly links acanthosis nigricans to the insulin-resistant phenotype.
- category: Endocrine/Metabolic
  name: Hypertriglyceridemia
  description: Hypertriglyceridemia is a highly penetrant metabolic manifestation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypertriglyceridemia
    term:
      id: HP:0002155
      label: Hypertriglyceridemia
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Insulin resistance is typically accompanied by the skin changes of acanthosis nigricans, and proceeds to T2DM in the majority by the third decade. Nearly all demonstrate hypertriglyceridemia."
    explanation: GeneReviews' "nearly all" wording directly supports the very-frequent band.
- category: Endocrine/Metabolic
  name: Type II diabetes mellitus
  description: Progressive hyperglycemia emerging as insulin resistance worsens over time.
  phenotype_term:
    preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
  evidence:
  - reference: PMID:33566311
    reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, infantile transient cardiomyopathy, early childhood obesity with hyperphagia, deafness, insulin resistance (IR), type 2 diabetes mellitus (T2DM), systemic fibrosis and progressive renal or liver dysfunction are common findings."
    explanation: Clinical review supports type II diabetes mellitus as a common downstream metabolic manifestation of ALMS.
- category: Cardiovascular
  name: Dilated cardiomyopathy
  description: >-
    Infantile or later-onset myocardial disease with ventricular dilation and
    systolic dysfunction; infantile episodes may partially recover while adult
    cardiomyopathy can progress.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  evidence:
  - reference: PMID:17594715
    reference_title: "Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alström syndrome is a monogenic recessive disorder featuring an array of clinical manifestations, with systemic fibrosis and multiple organ involvement, including retinal degeneration, hearing loss, childhood obesity, diabetes mellitus, dilated cardiomyopathy (DCM), urological dysfunction, and pulmonary, hepatic, and renal failure."
    explanation: Large genotype-phenotype study identifies dilated cardiomyopathy as a core multisystem feature of ALMS.
  - reference: PMID:38806112
    reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RESULTS: 47 adults with AS (64% male; mean age 33 years; 66% white British) were studied. Seven (15%) survived infantile cardiomyopathy and 23 (49%) developed adult-onset cardiomyopathy."
    explanation: Adult cardiovascular cohort shows cardiomyopathy is frequent across the lifespan.
- category: Cardiovascular
  name: Restrictive cardiomyopathy
  description: A later-onset restrictive cardiomyopathy is part of the biphasic cardiac spectrum.
  phenotype_term:
    preferred_term: Restrictive cardiomyopathy
    term:
      id: HP:0001723
      label: Restrictive cardiomyopathy
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alström syndrome is characterized by cone-rod dystrophy, obesity, progressive bilateral sensorineural hearing impairment, acute infantile-onset cardiomyopathy and/or adolescent- or adult-onset restrictive cardiomyopathy, insulin resistance / type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and chronic progressive kidney disease."
    explanation: GeneReviews explicitly includes adolescent- or adult-onset restrictive cardiomyopathy in the core clinical spectrum.
- category: Renal
  name: Chronic kidney disease
  description: Age-progressive primary kidney involvement with declining kidney function and proteinuria in a subset of adults.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Chronic kidney disease
    term:
      id: HP:0012622
      label: Chronic kidney disease
  evidence:
  - reference: PMID:30064963
    reference_title: "Alström syndrome: Renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eighteen percent met the definition for chronic kidney disease (eGFR < 60 mL/min/1.73 m2 and proteinuria); all were adults with median age of 32.8 (20.6-37.9) years."
    explanation: Prospective NIH cohort quantifies age-progressive chronic kidney disease in adults with ALMS.
- category: Hepatic
  name: Hepatic steatosis
  description: Common metabolic liver involvement that often coexists with early fibrogenic liver stiffness abnormalities.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:41466426
    reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
    explanation: Large cohort demonstrates frequent hepatic steatosis in ALMS.
- category: Hepatic
  name: Hepatic fibrosis
  description: Progressive fibrogenic liver involvement can accompany steatosis and increasing liver stiffness.
  phenotype_term:
    preferred_term: Hepatic fibrosis
    term:
      id: HP:0001395
      label: Hepatic fibrosis
  evidence:
  - reference: PMID:33924909
    reference_title: "Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with ALMS displayed enhanced steatosis, an early increased age-dependent LS that is associated with obesity and T2DM but also linked to genetic alterations, suggesting that ALMS1 could be involved in liver fibrogenesis."
    explanation: Human liver stiffness and steatosis data support progressive fibrogenic liver involvement while qualifying the causal contribution of ALMS1.
- category: Neurologic
  name: Motor delay
  description: Early gross or fine motor milestones are delayed in a minority of affected individuals.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 20% of affected individuals have delay in early developmental milestones, most commonly in gross and fine motor skills."
    explanation: The quantitative GeneReviews statement maps directly to the occasional frequency band.
- category: Neurologic
  name: Specific learning disability
  description: Learning disability occurs in a substantial minority, whereas global cognitive impairment is rare.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "About 30% have a learning disability. Cognitive impairment (IQ <70) is very rare."
    explanation: GeneReviews quantifies learning disability at 30%, supporting the frequent band and distinguishing it from rare global cognitive impairment.
diagnosis:
- name: Age-dependent clinical assessment
  description: >-
    Clinical suspicion rests on cardinal manifestations that emerge across
    infancy, childhood, and early adulthood; early cone-rod dystrophy,
    nystagmus, photophobia, infantile obesity, and cardiomyopathy are important
    red flags, but absence of a later feature does not exclude the diagnosis.
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical diagnosis of Alström syndrome is based on cardinal clinical features that emerge throughout infancy, childhood, and young adulthood."
    explanation: GeneReviews establishes the age-dependent clinical-diagnosis framework.
  - reference: PMID:39763001
    reference_title: "Alström syndrome: the journey to diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Obesity rapidly developing in infancy should be flagged as a key symptom to be aware of where AS is a possible diagnosis."
    explanation: A contemporary diagnostic-pathway cohort identifies rapidly developing infantile obesity as a red flag.
- name: Molecular genetic testing of ALMS1
  description: >-
    Molecular diagnosis is established by identifying biallelic pathogenic
    ALMS1 variants; testing is particularly important because the multisystem
    phenotype is progressive and age dependent.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The molecular diagnosis of Alström syndrome is established in individuals of all ages by identification of biallelic pathogenic variants in ALMS1 on molecular genetic testing."
    explanation: GeneReviews directly defines the confirmatory molecular test.
differential_diagnoses:
- name: Bardet-Biedl syndrome
  disease_term:
    preferred_term: Bardet-Biedl syndrome
    term:
      id: MONDO:0015229
      label: Bardet-Biedl syndrome
  description: >-
    Both conditions are autosomal recessive syndromic-obesity ciliopathies with
    retinal and renal involvement, making early clinical confusion possible.
  distinguishing_features:
  - Early cone-rod dystrophy, progressive sensorineural hearing loss, and cardiomyopathy favor Alstrom syndrome.
  - Postaxial polydactyly and the canonical BBS gene spectrum favor Bardet-Biedl syndrome.
  - Biallelic pathogenic variants in ALMS1 establish Alstrom syndrome.
  evidence:
  - reference: PMID:39763001
    reference_title: "Alström syndrome: the journey to diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 2/17 (12%) patients in our study received an incorrect diagnosis of Bardet-Biedl Syndrome and Leber Congenital Amaurosis"
    explanation: The diagnostic-pathway cohort documents real-world confusion with Bardet-Biedl syndrome and the resolving role of genetic testing.
treatments:
- name: GLP-1 Receptor Agonist Therapy
  description: >-
    Semaglutide or exenatide can improve weight, glycemia, and lipid parameters
    in adults with Alstrom syndrome and metabolically significant obesity or
    diabetes.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: semaglutide
      term:
        id: CHEBI:167574
        label: semaglutide
    - preferred_term: exendin-4
      term:
        id: CHEBI:64073
        label: exendin-4
  target_phenotypes:
  - preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  - preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
  evidence:
  - reference: PMID:38151964
    reference_title: "Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "completed 6 months of treatment with GLP-1 RAs either in the form of semaglutide or exenatide"
    explanation: The abstract identifies both agents used in the Alstrom syndrome cohort.
  - reference: PMID:38151964
    reference_title: "Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "equating to 6% weight loss (P < .01) and 1.1% absolute reduction in HbA1c (P < .01)"
    explanation: The abstract quantifies clinically relevant weight and glycemic improvements after six months.
- name: Reduced-Calorie Dietary Management
  description: >-
    A healthful reduced-calorie diet with restricted simple carbohydrate intake
    is a foundational management strategy for obesity and insulin resistance.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_phenotypes:
  - preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  - preferred_term: Insulin resistance
    term:
      id: HP:0000855
      label: Insulin resistance
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Obesity and insulin resistance are managed by a healthful, reduced-calorie diet with restricted simple carbohydrate intake and regular aerobic exercise."
    explanation: GeneReviews directly supports diet and exercise as foundational metabolic management.
- name: Hearing aid usage
  description: Sound amplification is beneficial for the common progressive sensory hearing loss of Alstrom syndrome.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: hearing aid usage
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:28573831
    reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
    explanation: Prospective audiology cohort supports hearing aids as routine symptomatic treatment for ALMS hearing loss.
- name: Cochlear implantation
  description: >-
    Cochlear implantation should be considered for severe or functionally
    limiting hearing loss not adequately managed with amplification.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:28573831
    reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
    explanation: Same cohort specifically identifies cochlear implantation as an option for more severe ALMS hearing loss.
- name: Genetic Counseling and Reproductive Planning
  description: >-
    Counseling explains autosomal recessive recurrence risks and the availability
    of carrier, prenatal, and preimplantation genetic testing once familial
    ALMS1 variants are known.
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: GeneReviews provides the autosomal recessive recurrence risks communicated in genetic counseling.
- name: Multisystem Surveillance
  description: >-
    Longitudinal monitoring should cover vision, hearing, growth and weight,
    cardiac imaging and electrophysiology, glucose control, lipids, liver and
    thyroid function, and regular renal laboratory and ultrasound assessment.
  action_category: MONITORING
  treatment_term:
    preferred_term: surveillance
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surveillance: Routine assessment of vision and hearing; weight, height, and body mass index; heart (including echocardiography and EKG in all individuals, and MRI in those age >18 years); postprandial c-peptide and glucose and HbA1C starting at age four years; lipid profile; plasma ALT, AST, and GGT concentrations; thyroid function."
    explanation: GeneReviews gives an age-aware multisystem surveillance schedule.
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twice-yearly CBC, electrolytes, BUN, creatinine, cystatin-C, uric acid, urinalysis. Renal and bladder ultrasound examinations every one to two years if symptomatic and/or if urinalysis is abnormal."
    explanation: GeneReviews specifies the renal laboratory and imaging cadence.
- name: Standard Heart Failure and Cardiomyopathy Management
  description: >-
    Dilated or restrictive cardiomyopathy and heart failure require standard
    guideline-directed cardiac management individualized to phenotype and age.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  - preferred_term: Restrictive cardiomyopathy
    term:
      id: HP:0001723
      label: Restrictive cardiomyopathy
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Standard therapy for heart failure / cardiomyopathy."
    explanation: GeneReviews explicitly recommends standard treatment for the cardiac manifestations.
- name: Avoidance of Glitazones in Cardiac Failure
  description: >-
    Diabetes management must account for multisystem disease; glitazone therapy
    is contraindicated when cardiac failure is present.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: avoidance of contraindicated medication
  evidence:
  - reference: PMID:20301444
    reference_title: "Alström Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therapy directed at one system may have adverse effects on other systems; for example, the use of glitazone therapy in diabetes mellitus is contraindicated in the presence of cardiac failure."
    explanation: GeneReviews directly states this disease-specific cross-system medication warning.
clinical_trials:
- name: NCT03746522
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Randomized placebo-controlled Phase III study of the MC4R agonist
    setmelanotide for obesity and hyperphagia in Bardet-Biedl and Alstrom
    syndromes. Only six participants had Alstrom syndrome, and the published
    ALMS-specific efficacy result was inconclusive.
  target_phenotypes:
  - preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: clinicaltrials:NCT03746522
    reference_title: "A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS)."
    explanation: ClinicalTrials.gov establishes the intervention, population, phase, and intended obesity/hyperphagia outcomes.
  - reference: PMID:36356613
    reference_title: "Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Setmelanotide resulted in significant bodyweight reductions in patients with Bardet-Biedl syndrome; however, these results were inconclusive in patients with Alström syndrome."
    explanation: The trial publication prevents extrapolation of the positive Bardet-Biedl result to the underpowered Alstrom subgroup.
  notes: Registry status checked on 2026-08-04; the study is completed.
- name: NCT03184584
  phase: PHASE_II
  status: TERMINATED
  description: >-
    Open-label rollover study of the investigational antifibrotic PBI-4050 in
    participants who completed an earlier sponsor study. The registry describes
    a combined Phase II/III design; represented as Phase II because the schema
    accepts one phase value and the cached summary calls it Phase II.
  evidence:
  - reference: clinicaltrials:NCT03184584
    reference_title: An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050."
    explanation: ClinicalTrials.gov establishes this disease-specific investigational study without implying efficacy.
  notes: Registry status checked on 2026-08-04; the study is terminated and no efficacy claim is made.
animal_models:
- species: Mouse (Mus musculus)
  genotype: Homozygous Alms1 gene-trap disruption (Alms1-/-)
  genes:
  - preferred_term: ALMS1
    term:
      id: hgnc:428
      label: ALMS1
  category: Knockout mouse
  description: >-
    Alms1-disrupted mice reproduce retinal degeneration, late-onset hearing
    loss, obesity, hyperinsulinemia, and insulin resistance, making them useful
    for the sensory and metabolic arms of the disease while not fully modeling
    the human cardiac spectrum.
  associated_phenotypes:
  - Obesity
  - Insulin resistance
  - Photoreceptor degeneration
  - Late-onset hearing loss
  evidence:
  - reference: PMID:16000322
    reference_title: "Alms1-disrupted mice recapitulate human Alström syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Alms1-/- mice develop features similar to patients with AS, including obesity, hypogonadism, hyperinsulinemia, retinal dysfunction and late-onset hearing loss."
    explanation: The foundational mouse-model paper documents multisystem phenotypic recapitulation.
experimental_models:
- name: ALMS1-knockout human iPSC-derived cardiomyocytes
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  conditions:
  - ALMS1 knockout
  - isogenic wild-type control
  cell_source: Human induced pluripotent stem cells differentiated into cardiomyocytes
  culture_system: Monolayer iPSC-derived cardiomyocyte culture
  publication: PMID:39243575
  modeled_mechanisms:
  - target: Cardiac Fibroelastotic Remodeling
    description: The model probes cell-autonomous contractile, calcium-handling, metabolic, and senescence effects of ALMS1 loss in cardiomyocytes.
    evidence:
    - reference: PMID:39243575
      reference_title: Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "To understand the role of ALMS1 in infantile cardiomyopathy, the reduction of ALMS1 protein seen in AS patients was modelled using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), in which ALMS1 was knocked out."
      explanation: The study explicitly establishes this human iPSC cardiomyocyte system as an infantile-cardiomyopathy model.
  findings:
  - statement: ALMS1 knockout alters cardiomyocyte contractility, calcium handling, energetics, and senescence.
    supporting_text: "MuscleMotion analysis and calcium optical mapping experiments suggest that ALMS1 knockout (KO) cells have increased contractility, with altered calcium extrusion and impaired calcium handling dynamics compared to wildtype (WT) counterparts."
    evidence:
    - reference: PMID:39243575
      reference_title: Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "MuscleMotion analysis and calcium optical mapping experiments suggest that ALMS1 knockout (KO) cells have increased contractility, with altered calcium extrusion and impaired calcium handling dynamics compared to wildtype (WT) counterparts."
      explanation: Directly reports abnormal contractility and calcium handling in the model.
  evidence:
  - reference: PMID:39243575
    reference_title: Characterisation of infantile cardiomyopathy in Alström syndrome using ALMS1 knockout induced pluripotent stem cell derived cardiomyocyte model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Overall, this study provides insights into the molecular mechanisms in AS, particularly the role of ALMS1 in infantile cardiomyopathy in AS, using iPSC-CMs as a 'disease in a dish' model to provide insights into multiple aspects of this complex disease."
    explanation: Supports the model's disease relevance while keeping its in-vitro evidence class explicit.
discussions:
- discussion_id: gap_alms_cardiomyopathy_model_fidelity
  prompt: >-
    Why do current Alms1-deficient mouse models reproduce adult cardiac
    dysfunction only incompletely and fail to reproduce infantile cardiomyopathy?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Cardiac Fibroelastotic Remodeling
  rationale: >-
    Human disease is biphasic, but global knockout mice had normal cardiac
    function at postnatal day 15 and eight weeks; only adult females developed
    early restrictive features. This sex- and age-limited phenotype constrains
    translation of mouse cardiac mechanisms and motivates complementary human
    iPSC and longitudinal in-vivo studies.
  evidence:
  - reference: PMID:38756069
    reference_title: Female Alms1-deficient mice develop echocardiographic features of adult but not infantile Alström syndrome cardiomyopathy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cardiac function was unaltered in Alms1 global KO mice of both sexes at postnatal day 15 (P15) and 8 weeks. At 23 weeks, female - but not male - KO mice showed increased left atrial area and decreased isovolumic relaxation time, consistent with early restrictive cardiomyopathy, as well as reduced ejection fraction."
    explanation: The mouse study directly documents failure to model infantile disease and sex-limited adult cardiac abnormalities.
references:
- reference: PMID:20301444
  title: "Alström Syndrome."
  tags:
  - GeneReviews
notes: >-
  Curated as a single ALMS1-related multisystem disease entity rather than split
  into separate retinal, cardiomyopathic, or metabolic disorders. Infantile
  cardiomyopathy and later adult-onset cardiomyopathy are modeled as
  age-dependent manifestations within the same disease.
datasets:
- accession: massive:MSV000099396
  title: Metabolomic data of ALMS1 WT and ALMS1 KO mice before and after symptoms of Alstrom syndrome
  description: RAW metabolomics data from Mus musculus liver, plasma and WAT used in - Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis. The dataset includes files from ALMS1 KO and WT mice (young and adult)
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: METABOLOMICS
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Alstrom Syndrome"). Retrieved 2026-08-02.
📚

References & Deep Research

References

1
PMID:20301444
Alström Syndrome.
No top-level findings curated for this source.

Deep Research

1
Manual Pubmed Review ▸
Alstrom Syndrome (ALMS1): Mechanistic Summary
n/a 16 citations 2026-04-12T20:45:00Z

Alstrom Syndrome (ALMS1): Mechanistic Summary

Disease framing and lumping/splitting

Alstrom syndrome should be curated as a single ALMS1-related multisystem ciliopathy, not split into separate retinal, cardiomyopathic, renal, or metabolic diseases. The strongest framing papers consistently describe one disorder with age-dependent expression spanning early cone/cone-rod retinal dystrophy, childhood obesity, progressive hearing loss, cardiomyopathy, and later renal/hepatic disease (PMID:11941369, PMID:11941370, PMID:17594715, PMID:41466426).

Infantile cardiomyopathy and adult cardiomyopathy are best treated as distinct manifestations within one disease course, not as separate disorders. Adult cardiovascular phenotyping shows that some infants recover from transient severe cardiomyopathy and later develop adult-onset disease, demonstrating variable expressivity rather than nosologically distinct entities (PMID:38806112).

The most important split decision is against Bardet-Biedl syndrome. Both are syndromic obesity ciliopathies, but Alstrom syndrome is distinguished by early cone/cone-rod dystrophy, progressive sensorineural hearing loss, and cardiomyopathy, while polydactyly and overt neurodevelopmental impairment are not defining Alstrom features. This distinction is reinforced in cohort and review literature used for differential diagnosis (PMID:28573831, PMID:30064963, PMID:39763001).

Genetics and inheritance

Alstrom syndrome is an autosomal recessive disorder caused by biallelic ALMS1 pathogenic variants (PMID:11941369, PMID:11941370). The original cloning studies showed recurrent nonsense and frameshift mutations causing premature truncation of ALMS1, establishing loss of function as the canonical disease mechanism (PMID:11941369, PMID:11941370).

Subsequent cohort work showed that pathogenic variants are concentrated especially in exons 8, 10, and 16, although the mutational spectrum is broad and still expanding (PMID:17594715, PMID:41466426). The largest recent Chinese cohort identified 132 distinct ALMS1 variants, 64 of them novel, with truncating variants predominating and exon 16 truncating alleles enriched among infantile cardiomyopathy cases (PMID:41466426).

Core mechanistic story

The core mechanistic lesion is ALMS1 dysfunction at the centrosome and ciliary basal body. Localization studies demonstrated that ALMS1 is widely expressed and localizes to centrosomes and the base of cilia, supporting a basal-body centered mechanism rather than a tissue-restricted defect (PMID:15855349). Kidney and cochlear studies extended this by showing roles in cilium maintenance, mechanosensation, and cilium-dependent planar cell polarity (PMID:17206865, PMID:21071598).

This basal-body lesion branches into several partially separable disease modules:

  1. Sensory-cell degeneration Photoreceptor and cochlear hair-cell maintenance depend on ALMS1. Alms1-disrupted mice show early cone ERG abnormalities followed by photoreceptor loss and rhodopsin mislocalization, supporting a trafficking-dependent retinal degeneration mechanism (PMID:16000322). In the cochlea, ALMS1 localizes to hair-cell basal bodies; loss causes hair-bundle polarity abnormalities, outer hair-cell loss, and progressive sensory hearing loss (PMID:21071598). Human cohort data align with this model: retinal disease is typically earliest, while hearing loss is childhood-onset, symmetric, and progressive (PMID:28573831, PMID:33566311, PMID:41466426).

  2. Adipose tissue failure and insulin-resistant obesity The best current human mechanistic paper is the adipose physiology study showing relative adipose tissue failure in ALMS as a major determinant of accelerated insulin resistance without frank lipodystrophy (PMID:32994277). This provides a stronger disease-specific explanation for the metabolic phenotype than generic statements about obesity alone. Review synthesis further argues that severe insulin resistance and later beta-cell failure together drive type II diabetes mellitus in ALMS (PMID:33566311).

  3. Extracellular matrix dysregulation and fibrosis Fibrosis is not just a descriptive phenotype but a central mechanistic axis of disease. The older genotype-phenotype paper already emphasizes systemic fibrosis (PMID:17594715). More recently, ALMS1 knockout fibroblast profiling showed extracellular matrix regulation and collagen fibril organization among the key processes altered by ALMS1 loss (PMID:38062477). Human liver studies using elastography and ultrasound found enhanced steatosis plus age-related liver stiffness in ALMS, supporting a fibrogenic liver phenotype linked both to metabolic burden and ALMS1-related mechanisms (PMID:33924909).

  4. Primary kidney ciliopathy Renal disease is best modeled as a primary manifestation of ALMS1 deficiency, not just downstream diabetic kidney disease. Mouse work demonstrated stunted kidney epithelial cilia and impaired calcium responses to mechanical stimuli after Alms1 knockdown (PMID:17206865). The NIH human cohort then showed that kidney dysfunction was not explained by diabetes, dyslipidemia, hypertension, cardiomyopathy, or portal hypertension after age adjustment, supporting primary kidney involvement (PMID:30064963).

  5. Cardiac fibroelastotic remodeling Cardiomyopathy in ALMS is mechanistically heterogeneous across the lifespan. Adults frequently develop cardiomyopathy with restrictive features and broader cardiovascular remodeling (PMID:38806112). A pathology-confirmed neonatal case linked ALMS1 deficiency to primary endocardial fibroelastosis, with accompanying EMT/TGF-beta pathway activation and increased cardiomyocyte proliferation in ALMS1-depleted systems (PMID:34387706). This supports keeping infantile fibroelastotic disease and later adult cardiomyopathy within one mechanistic cardiac spectrum rather than treating them as separate diseases.

Organ-specific curation takeaways

Retina

  • Strongest disease-level phenotype: progressive cone/cone-rod dystrophy with severe visual impairment (PMID:33566311, PMID:41466426).
  • Mechanistic support: photoreceptor trafficking/degeneration in Alms1 mouse models (PMID:16000322).

Hearing

  • Strongest disease-level phenotype: progressive sensorineural hearing impairment beginning in childhood (PMID:28573831).
  • Mechanistic support: outer hair cell lesion and cilium-dependent planar cell polarity defects (PMID:21071598).

Metabolism

  • Strongest mechanistic framing: obesity plus relative adipose tissue failure drives severe insulin resistance (PMID:32994277).
  • Human phenotype support for obesity and diabetes is abundant, but mechanistic specificity is best when grounded to adipose failure rather than generic “ciliary obesity” language (PMID:32994277, PMID:33566311, PMID:41466426).

Kidney

  • Human cohort evidence supports primary ALMS nephropathy (PMID:30064963).
  • Mouse evidence supports tubular ciliary mechanosensory dysfunction (PMID:17206865).

Liver

  • Human evidence supports common hepatic steatosis and increasing liver stiffness/fibrogenesis with age (PMID:33924909, PMID:41466426).

Heart

  • Human evidence supports frequent cardiomyopathy in both infancy and adulthood, with ongoing remodeling even after infantile improvement (PMID:38806112, PMID:41466426).
  • Histopathology-backed fibroelastosis is supported but rare enough to model as a supported histopathologic finding, not as the dominant disease definition (PMID:34387706).

Treatment evidence that is specific enough to curate

Only a small number of treatments have disease-specific abstract-level support strong enough for clean curation:

  1. GLP-1 receptor agonists Real-world cohort data in adults with ALMS show reductions in body weight and HbA1c after semaglutide or exenatide, with additional lipid and liver-enzyme improvement (PMID:38151964). This is the strongest current disease-specific obesity/diabetes treatment evidence.

  2. Auditory rehabilitation Prospective single-center audiology data specifically conclude that affected individuals benefit from sound amplification and, when needed, cochlear implantation (PMID:28573831).

General “multidisciplinary management” and “lifestyle modification” recommendations are common in reviews (PMID:33566311), but these are less specific than the GLP-1 and hearing-rehabilitation evidence above.

Curation boundaries

  • Use exact PMID-backed abstract quotes for evidence items.
  • Keep evidence_source aligned to the study type:
  • HUMAN_CLINICAL for cohort, case, and prospective phenotyping papers
  • MODEL_ORGANISM for mouse/rat mechanistic studies
  • IN_VITRO for fibroblast or cell-line mechanistic experiments
  • Avoid overclaiming a single “master pathway.” TGF-beta, endosomal recycling, AKT, ECM regulation, and ciliary polarity all appear in the literature, but the disease-level story is stronger when modeled as parallel downstream consequences of ALMS1 dysfunction than as one fully ordered linear cascade.

References

  • PMID:11941369
  • PMID:11941370
  • PMID:15855349
  • PMID:16000322
  • PMID:17206865
  • PMID:17594715
  • PMID:21071598
  • PMID:28573831
  • PMID:30064963
  • PMID:32994277
  • PMID:33566311
  • PMID:33924909
  • PMID:34387706
  • PMID:38062477
  • PMID:38151964
  • PMID:38806112
  • PMID:41466426